Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
My name is Paul Matteis. I'm a Biotech Analyst at Stifel. Happy to have Josh Brodsky, who runs Investor Relations at Alnylam, give us a presentation on Alnylam's progress. I think it's just going to be a presentation day because you guys have the R&D Day Friday, right? So Josh, you want to take it away?
Great. Okay. Thanks so much, Paul. Pleasure to be here. Thanks to you and the conference organizers for inviting Alnylam to participate. Good morning, everyone. My name is Josh Brodsky, I'm Director of Investor Relations and Corporate Communications at Alnylam. I will, of course, be making some forward-looking statements, and so I encourage you to review our most recent SEC filings for a more complete discussion of our risk factors.
Now as you may know, Alnylam has been the leader in advancing RNAi therapeutics as a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |